SIMOVIL 20 MG

Land: Israel

Språk: engelsk

Kilde: Ministry of Health

Aktiv ingrediens:

SIMVASTATIN 20 MG

Tilgjengelig fra:

MERCK SHARP & DOHME ISRAEL LTD

ATC-kode:

C10AA01

Legemiddelform:

TABLETS

Administreringsrute:

PER OS

Produsert av:

MERCK SHARP & DOHME B.V, HOLLAND

Terapeutisk gruppe:

SIMVASTATIN

Indikasjoner:

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simovil is indicated to: Reduce the risk of total mortality by reducing coronary death; Reduce the risk of non-fatal myocardial infarction; Reduce the risk for undergoing myocardial revascularization procedures; Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simovil is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia( heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simovil therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simovil is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglycerid

Autorisasjon dato:

2013-01-01